Business · Markets · 4 hrs ago
Neuren shares reach a 12-month high as Daybue sales rise
Neuren Pharmaceuticals shares reached a 12-month high on 5 November after an update on sales of Daybue.
Neuren, an Australian drug company, developed Daybue to treat Rett syndrome and licensed it to US partner Acadia Pharmaceuticals.
Daybue sales rose 39% year over year in the third quarter, reaching US$140 million.
Acadia raised its forecast for full-year sales to US$505 million to US$520 million, and Neuren increased its expected licensing earnings.
Daybue launched in Germany in October, bringing Neuren a US$35 million milestone payment; the company is also seeking approval in Japan.
Neuren is testing NNZ-2591 for several rare conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.
The FDA has granted it orphan drug designation for potential treatment of neonatal hypoxic-ischemic encephalopathy, and a Phase 3 trial is under way in children with Phelan-McDermid syndrome.
Neuren Pharmaceuticals shares reached a 12-month high of $23.76 on 5 November after the company reported rising Daybue sales.
Daybue net sales rose 39% in the third quarter from the same period a year earlier to US$140 million.
Acadia Pharmaceuticals raised its full-year Daybue sales guidance to US$505 million to US$520 million.
Neuren increased its expected Daybue licensing earnings to US$91 million to US$93 million.
Daybue launched in Germany in October, triggering a US$35 million milestone payment to Neuren.
- Who
- Neuren Pharmaceuticals and its US partner, Acadia Pharmaceuticals.
- What
- Neuren shares reached a 12-month high after an update showed Daybue sales growth and higher sales guidance.
- When
- 5 November 2026.
- Where
- Neuren shares trade on the Australian Securities Exchange; Daybue launched in Germany in October.
- Why
- Daybue sales rose, leading Acadia to increase its full-year sales guidance and Neuren to raise its expected licensing earnings.
This story does not have two clearly opposing sides.
Bell Potter tipped that Neuren shares would reach $23.50 within 12 months.
Daybue net sales rose 39% from the same period in 2025 to US$140 million.
Daybue launched in Germany, earning Neuren a US$35 million milestone payment.
Neuren shares reached a 12-month high of $23.76 after the company released a Daybue sales update.
- Share price high
- $23.76 on 5 November
- Daybue Q3 net sales
- US$140 million
- Year-on-year sales growth
- 39%
- Acadia full-year sales guidance
- US$505 million to US$520 million
- Neuren expected licensing earnings
- US$91 million to US$93 million
- Germany launch milestone payment
- US$35 million
1 source
What people are saying
The Neuren team is excited about the impressive performance of Daybue in Q3 2026 and an outlook that continues to strengthen.